Next in the sequence

After a tumultuous few months, 23andMe filed for Chapter 11 bankruptcy. While 23andMe’s bankruptcy marks the end of a pioneering era in consumer genetics, it doesn’t signal the end of momentum in consumer health testing and diagnostic innovation. Diagnostics players are advancing genomic testing capabilities and generating personalized health insights via tech partnerships, while EHRs are integrating genetic data into patient records—with AI-enabled features that surface real-time insights for care plans. Consumer-facing testing startups are still raising, and young consumers show the most interest of any generation in at-home testing across fertility, microbiome, and hormone health. 23andMe's assets will likely find a home via acquisition, and the company’s legacy will inform others’ pathways in the space. Raising capital responsibly, finding a sustainable business model, and adopting consumer health data best practices are non-negotiables for industry success.

Headlines

HHS Cuts 10K Employees In Major Overhaul Of Health Agencies
Drug, medical device positions unaffected; meanwhile, Senate confirms FDA, NIH leadership CNN

Recent Funding

• AI-based, provider-focused patient management solution Navina pounces on $55M
• Silna Health picks up $27M for its AI-powered revenue management and prior auth solution
• Layer Health wraps up $21M for its LLM for chart review and clinical workflow optimization
• Medical billing and coding startup Taxo launches with $5M